Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, April 20 2023 - 21:00
AsiaNet
Sai Life Sciences opens SSRL, a dedicated research facility for Schrodinger, at its Hyderabad R&D Campus
HYDERABAD, India, April 20, 2023 /PRNewswire-AsiaNet/ --

    - Fully equipped labs with 75-member team set-up and made operational in 
<100 days

    Sai Life Sciences, one of India's fastest growing global Contract Research, 
Development & Manufacturing Organisations (CRO-CDMO) 
[https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=ssrl-inaugur
ation], today announced the opening of Sai Schrodinger Research Laboratories 
(SSRL) at its R&D campus in Hyderabad, India. The facility was inaugurated by 
Dr. Karen Akinsanya, President of R&D, Therapeutics at Schrodinger Inc., in the 
presence of members of the leadership team of Schrödinger and Sai Life Sciences.

    Inaugurating the facility, Dr. Karen Akinsanya said, "We selected Sai Life 
Sciences as our CRO late last year, and we are extremely pleased that they are 
now poised to begin work on our programs with a highly experienced and 
dedicated team at a state-of-the-art facility. Sai Life Sciences will play an 
important role in advancing our drug discovery and early development 
activities, and we look forward to working closely together."

    In January 2023, Sai Life Sciences entered into a 5-year strategic 
agreement with Schrodinger, whose physics-based computational platform is 
transforming the way therapeutics and materials are discovered, to set up SSRL 
in Hyderabad, India. Soon after, Sai Life Sciences commenced the build-up of 
the facility along with recruitment of scientific staff, to drive the project 
to completion in an accelerated time frame.

    Speaking at the occasion, Krishna Kanumuri, CEO & Managing Director, Sai 
Life Sciences, said, "Our collaboration with Schrodinger marks an exciting new 
start for us at Sai Life Sciences, with a dedicated facility to support 
multiple discovery programs. The trust they've placed in us is a testimony to 
the advances we have made in the scale, scope and depth of our integrated drug 
discovery capabilities. I look forward to a productive collaboration."

    On the occasion, Dr. Karen Akinsanya and Krishna Kanumuri, met notable 
officials representing the Hon'ble Minister for Industries & Commerce, 
Government of Telangana, Shri KT Rama Rao, to apprise them of the nature of the 
collaboration and the role that Sai Schrödinger Research Laboratories (SSRL) 
will play in advancing drug discovery and development.

    Set up inside Sai Life Sciences' R&D campus in Genome Valley, SSRL is a 
dedicated facility for integrated discovery 
[https://www.sailife.com/services/discovery/integrated-drug-discovery-services/?
utm_source=pr&utm_medium=web&utm_campaign=ssrl-inauguration] work streams 
including medicinal & synthetic chemistry 
[https://www.sailife.com/services/discovery/synthetic-medicinal-chemistry/?utm_s
ource=pr&utm_medium=web&utm_campaign=ssrl-inauguration], in vitro biology 
[https://www.sailife.com/services/discovery/biology/?utm_source=pr&utm_medium=we
b&utm_campaign=ssrl-inauguration], and process chemistry 
[https://www.sailife.com/services/discovery/computational-chemistry-services/?ut
m_source=pr&utm_medium=web&utm_campaign=ssrl-inauguration]. SSRL will access 
other Sai capabilities such as in vitro ADME 
[https://www.sailife.com/services/discovery/dmpk-in-vitro-adme/?utm_source=pr&ut
m_medium=web&utm_campaign=ssrl-inauguration] and in vivo PK 
[https://www.sailife.com/services/discovery/dmpk-in-vivo-pk/?utm_source=pr&utm_m
edium=web&utm_campaign=ssrl-inauguration] as needed. The relationship will 
support advancement of programs that leverage Schrödinger's validated 
computational platform. Currently, SSRL has 75 employees across 
full-time-equivalents (FTEs) in Medicinal Chemistry, Biology, Process Chemistry 
and Analytical Chemistry. 

    About Sai Life Sciences

    Sai Life Sciences is a full-service CRO-CDMO that works with over 200 
innovator pharma and biotech companies globally, to accelerate the discovery, 
development, and commercialisation of complex small molecules. The company has 
over 2600 employees across its facilities in India, UK and USA. Sai Life 
Sciences is privately held and backed by global investors, TPG Capital and HBM 
Healthcare Investments. https://www.sailife.com/

    Photo: https://mma.prnewswire.com/media/2059072/SSRL_Hyderabad_Campus.jpg
    Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

    Source: Sai Life Sciences
Translations

Japanese